The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Updates from the Phase II trials of glofitamab and epcoritamab for R/R LBCL
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discusses updates from the pivotal Phase II studies of glofitamab and epcoritamab in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) who have had two or more prior lines of treatment. Dr Hutchings comments on durable response rates, suggesting a curative potential for both drugs. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So at ASH, we also see updates from the pivotal Phase II studies of glofitamab and epcoritamab in relapsed/refractory large B-cell lymphoma patients with two or more prior lines of treatment. These are the studies that have already led to the approval of these two CD3 and CD20 bispecific antibodies in this space, both in the US and Europe and many other regions. So at this meeting, we see updates from this study...
So at ASH, we also see updates from the pivotal Phase II studies of glofitamab and epcoritamab in relapsed/refractory large B-cell lymphoma patients with two or more prior lines of treatment. These are the studies that have already led to the approval of these two CD3 and CD20 bispecific antibodies in this space, both in the US and Europe and many other regions. So at this meeting, we see updates from this study. So the response rates are more or less the same, obviously, because the patients have all finished their induction treatment, and very few of the patients in the epcoritamab study, where the drug is given until progression, are still on treatment. So what we’re looking at is really the durability, and we see really promising durability, and stronger and stronger suggestive of a curative potential for both drugs in this space, even given as single agents as they are in these studies. So now with median follow-up extending more than two years and beyond three years actually, we see a median progression-free, sorry, median duration of complete response for epcoritamab around 36 months and a median duration of the CRs in the glofitamab study of around 30 months. Difficult to compare head to head. Progression-free survival curves can be tricky because very small differences can lead to large differences in median duration. But still, these are really promising data showing that approximately 50% of patients who achieve a CR have maintained CR for at least two to three years after the beginning of treatment. As I said, strongly suggestive of a curative potential for both drugs.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
AstraZeneca: Membership on an entity’s Board of Directors or advisory committees, Research Funding; BMS/Celgene: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; AbbVie: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Takeda: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Genmab: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Genentech: Research Funding; Incyte: Research Funding; Janssen/J&J: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Merck: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Novartis: Research Funding.
